NASDAQ:PSNLPersonalis Stock Price, Forecast & News

$11.84

+0.06 (+0.51 %)

(As of 05/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$11.23

Now: $11.84▼

$12.13

50-Day Range

$7.91

MA: $10.31▼

$12.62

52-Week Range

$4.27

Now: $11.84▼

$31.88

Volume225,764 shs

Average Volume252,926 shs

Market Capitalization$375.45 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT platform, a clinical-grade, next generation sequencing and analysis platform that enables the development of ImmunoID NeXT tumor biopsy and liquid biopsy, as well as provides analysis of tumor and immune microenvironment from a single limited tissue sample, tumor molecular profiling for cancer patients, and anticipates future cancer biomarkers. The company also provides accuracy and content enhanced platform (ACE) that enhances nucleic acid preparation processes and combines it with patented assay and sequencing methods. ACE Platform offers multiple products and services, such as ACE extended cancer panel for DNA and RNA, and ACE cancer research Exome and Transcriptome. In addition, it develops NeXT Dx test, which helps oncologists to identify potential therapies and clinical trial options for cancer patients, as well as offers whole genome sequencing, which provides DNA sequencing and data analysis services; and ACE CancerPlus Test. The company also provides a liquid biopsy assay that analyzes various human genes versus the more narrowly focused liquid biopsy assays that are currently available. It serves approximately 50 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Personalis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $22.25, Personalis has a potential upside of 87.9% from its current price of $11.84.
Amount of Analyst Coverage
Personalis has only been the subject of 2 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Personalis has received 61 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Personalis has received 56 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Personalis has received 52.14% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Personalis and other stocks. Vote “Outperform” if you believe PSNL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PSNL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Personalis does not currently pay a dividend.
Dividend Growth
Personalis does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Personalis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,840.00 in company stock.
Percentage Held by Insiders
Only 8.20% of the stock of Personalis is held by insiders.
Percentage Held by Institutions
60.92% of the stock of Personalis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Personalis are expected to grow in the coming year, from ($1.22) to ($0.98) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Personalis is -7.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Personalis is -7.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Personalis has a P/B Ratio of 3.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.55 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Medical laboratories

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:PSNL

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.personalis.com

Phone650-752-1300

Debt

Debt-to-Equity RatioN/A

Current Ratio2.60

Quick Ratio2.47

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$65.21 million

Price / Sales5.76

Cash FlowN/A

Price / Cash FlowN/A

Book Value$3.13 per share

Price / Book3.78

Profitability

EPS (Most Recent Fiscal Year)($1.39)

Net Income$-25,080,000.00

Net Margins-40.60%

Return on Equity-26.28%

Return on Assets-17.28%

Miscellaneous

Employees181

Outstanding Shares31,710,000

Market Cap$375.45 million

Next Earnings Date8/11/2020 (Estimated)

OptionableNot Optionable

Receive PSNL News and Ratings via Email

Sign-up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter.

Personalis (NASDAQ:PSNL) Frequently Asked Questions

How has Personalis' stock been impacted by COVID-19 (Coronavirus)?

Personalis' stock was trading at $6.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PSNL shares have increased by 96.7% and is now trading at $11.84. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Personalis?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Personalis.

When is Personalis' next earnings date?

Personalis is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Personalis.

How were Personalis' earnings last quarter?

Personalis (NASDAQ:PSNL) released its quarterly earnings results on Thursday, May, 7th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.03. The firm had revenue of $19.16 million for the quarter, compared to the consensus estimate of $16.80 million. Personalis had a negative net margin of 40.60% and a negative return on equity of 26.28%. View Personalis' earnings history.

What price target have analysts set for PSNL?

5 Wall Street analysts have issued 12-month price objectives for Personalis' shares. Their forecasts range from $14.00 to $29.00. On average, they expect Personalis' stock price to reach $22.25 in the next year. This suggests a possible upside of 87.9% from the stock's current price. View analysts' price targets for Personalis.

Has Personalis been receiving favorable news coverage?

Press coverage about PSNL stock has been trending very negative on Saturday, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Personalis earned a media sentiment score of -3.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutPersonalis.

Are investors shorting Personalis?

Personalis saw a decline in short interest in May. As of May 15th, there was short interest totaling 1,500,000 shares, a decline of 11.2% from the April 30th total of 1,690,000 shares. Based on an average daily trading volume, of 373,900 shares, the short-interest ratio is currently 4.0 days. Currently, 9.2% of the company's stock are sold short. View Personalis' Current Options Chain.

Who are some of Personalis' key competitors?

Some companies that are related to Personalis include CareDx (CDNA), Veracyte (VCYT), RadNet (RDNT), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Centogene (CNTG), DermTech (DMTK), Enzo Biochem (ENZ), Celcuity (CELC), Anpac Bio-Medical Science (ANPC), Miragen Therapeutics (MGEN), Biocept (BIOC), Psychemedics (PMD), OpGen (OPGN) and PotNetwork (POTN). View all competitors.

What other stocks do shareholders of Personalis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Editas Medicine (EDIT), Canopy Growth (CGC), Ford Motor (F), Flexion Therapeutics (FLXN), Proteostasis Therapeutics (PTI), Enphase Energy (ENPH), Energy Transfer LP Unit (ET), Inovio Pharmaceuticals (INO), NIO (NIO) and Viking Therapeutics (VKTX).

Who are Personalis' key executives?

Personalis' management team includes the following people:

Mr. John Stephen West, Co-Founder, CEO, Pres & Director (Age 63, Pay $785.44k)
Mr. Aaron L. Tachibana, Chief Financial Officer (Age 59, Pay $494.4k)
Dr. Richard Chen M.S., M.D., MS, Chief Scientific Officer (Age 49, Pay $543.75k)
Prof. Russ B. Altman, Co-Founder and Member of Clinical & Scientific Advisory Board
Mr. Euan A. Ashley, Co-Founder and Member of Clinical & Scientific Advisory Board

When did Personalis IPO?

(PSNL) raised $100 million in an IPO on Thursday, June 20th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is Personalis' stock symbol?

Personalis trades on the NASDAQ under the ticker symbol "PSNL."

Who are Personalis' major shareholders?

Personalis' stock is owned by a variety of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (4.95%), BlackRock Inc. (4.81%), Nikko Asset Management Americas Inc. (3.86%), Nikko Asset Management Americas Inc. (3.86%), Sumitomo Mitsui Trust Holdings Inc. (3.86%) and Wellington Shields Capital Management LLC (1.75%). Company insiders that own Personalis stock include Ken Ludlum and Richard Chen. View institutional ownership trends for Personalis.

Which major investors are selling Personalis stock?

PSNL stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Nuveen Asset Management LLC, Squarepoint Ops LLC, and Alambic Investment Management L.P.. View insider buying and selling activity for Personalis.

Which major investors are buying Personalis stock?

PSNL stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., BlackRock Inc., Wellington Shields Capital Management LLC, Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Gabelli Funds LLC, and State Street Corp. View insider buying and selling activity for Personalis.

How do I buy shares of Personalis?

Shares of PSNL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Personalis' stock price today?

One share of PSNL stock can currently be purchased for approximately $11.84.

How big of a company is Personalis?

Personalis has a market capitalization of $375.45 million and generates $65.21 million in revenue each year. The company earns $-25,080,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. Personalis employs 181 workers across the globe.

What is Personalis' official website?

The official website for Personalis is www.personalis.com.

How can I contact Personalis?

Personalis' mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company can be reached via phone at 650-752-1300 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff